A meta-analysis was performed to evaluate the accuracy of determination of procalcitonin (PCT) and C-reactive protein (CRP) levels for the diagnosis of bacterial infection. The analysis included published studies that evaluated these markers for the diagnosis of bacterial infections in hospitalized patients. PCT level was more sensitive (88% [95% confidence interval [CI], 80%-93%] vs. 75% [95% CI, 62%-84%]) and more specific (81% [95% CI, 67%-90%] vs. 67% [95% CI, 56%-77%]) than CRP level for differentiating bacterial from noninfective causes of inflammation. The Q value for PCT markers was higher (0.82 vs. 0.73). The sensitivity for differentiating bacterial from viral infections was also higher for PCT markers (92% [95% CI, 86%-95%] vs. 86% [95% CI, 65%-95%]); the specificities were comparable (73% [95% CI, 42%-91%] vs. 70% [95% CI, 19%-96%]). The Q value was higher for PCT markers (0.89 vs. 0.83). PCT markers also had a higher positive likelihood ratio and lower negative likelihood ratio than did CRP markers in both groups. On the basis of this analysis, the diagnostic accuracy of PCT markers was higher than that of CRP markers among patients hospitalized for suspected bacterial infections.

/pdf/serum-procalcitonin-and-c-reactive-protein-levels-as-markers-510g6f49jv.pdf

Serum Procalcitonin and C-Reactive Protein Levels as Markers of Bacterial Infection: A Systematic Review and Meta-analysis

Background The majority of patients undergoing surgical treatment for ST-elevation myocardial infarction receive antifibrinolytic therapy to limit blood loss. This approach appears counterintuitive to the accepted medical treatment of the same condition — namely, fibrinolysis to limit thrombosis. Despite this concern, no independent, large-scale safety assessment has been undertaken. Methods In this observational study involving 4374 patients undergoing revascularization, we prospectively assessed three agents (aprotinin [1295 patients], aminocaproic acid [883], and tranexamic acid [822]) as compared with no agent (1374 patients) with regard to serious outcomes by propensity and multivariable methods. (Although aprotinin is a serine protease inhibitor, here we use the term antifibrinolytic therapy to include all three agents.) Results In propensity-adjusted, multivariable logistic regression (C-index, 0.72), use of aprotinin was associated with a doubling in the risk of renal failure requiring dialysis am...

The risk associated with aprotinin in cardiac surgery.

BACKGROUND: Concerns regarding the safety of transfused blood have led to the development of a range of interventions to minimise blood loss during major surgery. Anti-fibrinolytic drugs are widely used, particularly in cardiac surgery, and previous reviews have found them to be effective in reducing blood loss, the need for transfusion, and the need for re-operation due to continued or recurrent bleeding. In the last few years questions have been raised regarding the comparative performance of the drugs. The safety of the most popular agent, aprotinin, has been challenged, and it was withdrawn from world markets in May 2008 because of concerns that it increased the risk of cardiovascular complications and death. OBJECTIVES: To assess the comparative effects of the anti-fibrinolytic drugs aprotinin, tranexamic acid (TXA), and epsilon aminocaproic acid (EACA) on blood loss during surgery, the need for red blood cell (RBC) transfusion, and adverse events, particularly vascular occlusion, renal dysfunction, and death. SEARCH STRATEGY: We searched: the Cochrane Injuries Group's Specialised Register (July 2010), Cochrane Central Register of Controlled Trials (The Cochrane Library 2010, Issue 3), MEDLINE (Ovid SP) 1950 to July 2010, EMBASE (Ovid SP) 1980 to July 2010. References in identified trials and review articles were checked and trial authors were contacted to identify any additional studies. The searches were last updated in July 2010. SELECTION CRITERIA: Randomised controlled trials (RCTs) of anti-fibrinolytic drugs in adults scheduled for non-urgent surgery. Eligible trials compared anti-fibrinolytic drugs with placebo (or no treatment), or with each other. DATA COLLECTION AND ANALYSIS: Two authors independently assessed trial quality and extracted data. MAIN RESULTS: This review summarises data from 252 RCTs that recruited over 25,000 participants. Data from the head-to-head trials suggest an advantage of aprotinin over the lysine analogues TXA and EACA in terms of reducing perioperative blood loss, but the differences were small. Compared to control, aprotinin reduced the probability of requiring RBC transfusion by a relative 34% (relative risk [RR] 0.66, 95% confidence interval [CI] 0.60 to 0.72). The RR for RBC transfusion with TXA was 0.61 (95% CI 0.53 to 0.70) and was 0.81 (95% CI 0.67 to 0.99) with EACA. When the pooled estimates from the head-to-head trials of the two lysine analogues were combined and compared to aprotinin alone, aprotinin appeared more effective in reducing the need for RBC transfusion (RR 0.90; 95% CI 0.81 to 0.99).Aprotinin reduced the need for re-operation due to bleeding by a relative 54% (RR 0.46, 95% CI 0.34 to 0.62). This translates into an absolute risk reduction of 2% and a number needed-to-treat (NNT) of 50 (95% CI 33 to 100). A similar trend was seen with EACA (RR 0.32, 95% CI 0.11 to 0.99) but not TXA (RR 0.80, 95% CI 0.55 to 1.17). The blood transfusion data were heterogeneous and funnel plots indicate that trials of aprotinin and the lysine analogues may be subject to publication bias.When compared with no treatment aprotinin did not increase the risk of myocardial infarction (RR 0.87, 95% CI 0.69 to 1.11), stroke (RR 0.82, 95% CI 0.44 to 1.52), renal dysfunction (RR 1.10, 95% CI 0.79 to 1.54) or overall mortality (RR 0.81, 95% CI 0.63 to 1.06). Similar trends were seen with the lysine analogues, but data were sparse. These data conflict with the results of recently published non-randomised studies, which found increased risk of cardiovascular complications and death with aprotinin. There are concerns about the adequacy of reporting of uncommon events in the small clinical trials included in this review.When aprotinin was compared directly with either, or both, of the two lysine analogues it resulted in a significant increase in the risk of death (RR 1.39, 95% CI 1.02, 1.89), and a non-significant increase in the risk of myocardial infarction (RR 1.11 95% CI 0.82, 1.50). Most of the data contributing to this added risk came from a single study - the BART trial (2008). AUTHORS' CONCLUSIONS: Anti-fibrinolytic drugs provide worthwhile reductions in blood loss and the receipt of allogeneic red cell transfusion. Aprotinin appears to be slightly more effective than the lysine analogues in reducing blood loss and the receipt of blood transfusion. However, head to head comparisons show a lower risk of death with lysine analogues when compared with aprotinin. The lysine analogues are effective in reducing blood loss during and after surgery, and appear to be free of serious adverse effects.

/pdf/anti-fibrinolytic-use-for-minimising-perioperative-2mv3d62q1l.pdf

Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion

http://cardiacanaesthesia.in/assets/img/guidelines/Perioperative-Blood-Transfusion-and-Blood-Conservation-in-Cardiac-Surgery.pdf

Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline.

Computational Analysis of Microarray Data

Mitral valve replacement (MVR) is still associated with a relatively high mortality. To prove the benefits of chordal preservation at mitral valve replacement, we investigated its effects in a series of 65 consecutive MVR patients. Of those patients, in 42 preservation of the mitral subvalvular structures was possible whereas in the other 23 they had to be excised. Both groups showed no differences in age, sex, preoperative NYHA class, and valve pathology. Intra- and postoperative management was similar in both groups. The surgical techniques employed are described and the early postoperative course of both groups are analysed. Clinical, electrocardiographic and echocardiographic investigations, measuring left-atrial and -ventricular diameters, right-ventricular diameters and left-ventricular length, demonstrated that whereas beneficial effects were evident in both groups, the amount of benefits was higher in patients with chordal preservation. Chordal preservation also provided less arrhythmias than chordal resection.

Mitral valve replacement with preservation of the subvalvular structures where possible: an echocardiographic and clinical comparison with cases where preservation was not possible. Surgical technique and early postoperative course.

Described is a device for supporting the functioning of the heart, the device having the following features: at least one housing (2) whose internal and external shape is such that it can be inserted in the human rib cage so that it at least partly surrounds the heart (1) with the exception of the vessels leading to and away from the heart; located in the housing(s) (2) is at least one chamber (4) which can be inflated by gas and which presses against the walls of the cavity; a control unit controls a pneumatic drive which fills and empties the individual chambers (4) in such a way that the chambers (4) press, in synchrony with the action of the heart, on at least the left ventricle of the heart so that blood is pressed into the aorta.

Device for supporting the functioning of the heart

Norepinephrine-induced delayed cardioprotection against stunning is at the expense of a higher postischemic arrhythmia rate

BACKGROUND Aortic valve replacement (AVR) with a 21-mm sized bioprothesis is still discussed controversially. Since better results have been reported for pericardial valves, the aim of the current study was to analyze the hemodynamic performance as well as clinical parameters in our patients and to compare pericardial and standard porcine valves in particular. METHODS 342 patients underwent AVR with a bioprosthesis between 1987 and 2000. A 21 mm prosthesis was used in 39 patients (group S), while 303 patients received at least a 23-mm sized valve (group L). Group S was further divided into 19 patients with a pericardial valve (group S1) and 20 patients with a standard porcine valve (group S2). The hemodynamic and clinical parameters were studied in all three groups. RESULTS The peak and mean transprosthetic gradients were significantly lower in the pericardial group than in the porcine group, particularly between patients with 21 mm valves (peak/mean: S1: 24 +/- 9/20.8 +/- 6.5 mm Hg vs. S2: 38 +/- 15/33 +/- 9 mm Hg, p < 0.05) at discharge. We could also observe that the peak transprosthetic gradient 7 days postoperatively was not significantly higher in patients with a 21 mm pericardial valve compared to group L patients. Comparing clinical parameters, we found significantly more cerebral ischemic events, a prolonged mechanical ventilation, a higher mortality and a longer stay in hospital in the group S2 compared to the group S1. CONCLUSION The current study shows that pericardial valves perform well, particularly in patients with small aortic roots. Postoperative hemodynamics and clinical results were better than for comparable standard porcine valves. As the outcome of patients with a 21 mm pericardial valve was no worse than that in patients with bigger valves, enlarging procedures for the aortic root are not necessary in the majority of these patients.

Hemodynamic performance and clinical consequences of aortic valve replacement with 21-mm sized pericardial bioprostheses.

This paper presents a new cardiac support device for left ventricular failure which consists of two inflatable bellows positioned dorsally and ventrally to the left ventricle. The implantable multi...

Peter Feindt

Papers

Mitral valve replacement with preservation of the subvalvular structures where possible: an echocardiographic and clinical comparison with cases where preservation was not possible. Surgical technique and early postoperative course.

Device for supporting the functioning of the heart

Norepinephrine-induced delayed cardioprotection against stunning is at the expense of a higher postischemic arrhythmia rate

Hemodynamic performance and clinical consequences of aortic valve replacement with 21-mm sized pericardial bioprostheses.

A new method of mechanical circulatory support with an implantable multichamber pump system (IMPS): presentation and first experimental results.